Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI108772

Interaction between High Density and Low Density Lipoproteins during Uptake and Degradation by Cultured Human Fibroblasts

N. E. Miller, D. B. Weinstein, T. E. Carew, T. Koschinsky, and D. Steinberg

Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California 92093

Find articles by Miller, N. in: PubMed | Google Scholar

Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California 92093

Find articles by Weinstein, D. in: PubMed | Google Scholar

Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California 92093

Find articles by Carew, T. in: PubMed | Google Scholar

Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California 92093

Find articles by Koschinsky, T. in: PubMed | Google Scholar

Division of Metabolic Disease, Department of Medicine, University of California, San Diego, La Jolla, California 92093

Find articles by Steinberg, D. in: PubMed | Google Scholar

Published July 1, 1977 - More info

Published in Volume 60, Issue 1 on July 1, 1977
J Clin Invest. 1977;60(1):78–88. https://doi.org/10.1172/JCI108772.
© 1977 The American Society for Clinical Investigation
Published July 1, 1977 - Version history
View PDF
Abstract

High density lipoprotein (HDL) inhibited the binding (trypsin-releasable radioactivity), internalization (cell-associated radioactivity after trypsinization), and degradation (TCA-soluble non-iodide radioactivity) of 125I-low density lipoprotein (125I-LDL) by cultured normal human fibroblasts. At HDL:LDL molar ratios of 25:1 (protein ratios about 5:1), these parameters were reduced by about 25%. Unlabeled LDL was about 25 times more effective in reducing 125I-LDL binding, implying that if HDL and LDL bind at common sites the affinity of HDL for these sites is very low or that the interaction is on some other basis. The fractional reduction in 125I-LDL binding at a given HDL: 125I-LDL ratio was independent of 125I-LDL concentration and occurred equally with fibroblasts from a subject with homozygous familial hypercholesterolemia. Reciprocally, the binding, internalization, and degradation of 125I-HDL were reduced by LDL. Preincubation of fibroblasts with HDL (or LDL) reduced the subsequent binding of 125I-LDL (or 125I-HDL) during a second incubation. In other studies HDL reduced the net increase in cell cholesterol content induced by incubation with LDL. HDL alone had no net effect on cell cholesterol content.

These findings suggest that HDL reduces both the high affinity and the low affinity binding of LDL to human fibroblasts and that this in turn reduces the internalization and degradation of LDL. The effect of HDL on the LDL-induced changes in cell cholesterol content could be in part on this basis and in part on the basis of an HDL-stimulated release of cholesterol from the cells. These effects of HDL in vitro may be relevant to the negative correlations reported from in vivo studies between plasma HDL concentration and both body cholesterol pool size and the prevalence of clinically manifest atherosclerosis but further studies will be needed to establish this.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 78
page 78
icon of scanned page 79
page 79
icon of scanned page 80
page 80
icon of scanned page 81
page 81
icon of scanned page 82
page 82
icon of scanned page 83
page 83
icon of scanned page 84
page 84
icon of scanned page 85
page 85
icon of scanned page 86
page 86
icon of scanned page 87
page 87
icon of scanned page 88
page 88
Version history
  • Version 1 (July 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts